Amidst the triumph of medicinal innovation, Ocugen s financial narrative reveals another chapter of resilience and recovery. The company s Total Debt to Equity ratio, despite the spectre of borrowings casting shadows on its balance sheets, narrates a tale of fiscal triumph. Achieving an all-time high following a debt repayment of -3. 49% in Q1 2025, the Total Debt to Equity ratio improved markedly to 0.6. This evolution is testament not only to Ocugen s commitment to scientific progress but also to their strategic acumen in financial stewardship.